Skip to content

Quick ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.4×+4.3×
Summit Therapeutics logo
Summit TherapeuticsSMMT
7.4×-3.2×
Exelixis logo
ExelixisEXEL
3.1×-0.2×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
6.8×-6.7×
Incyte logo
IncyteINCY
3.5×+1.6×

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Calculated from Nuvalent, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s quick ratio?
Nuvalent, Inc. (NUVL) reported quick ratio of 16.1× in Q1 2026.
How has Nuvalent, Inc.'s quick ratio changed year-over-year?
Nuvalent, Inc.'s quick ratio increased by 11.4% year-over-year, from 14.5× to 16.1×.
What is the long-term trend for Nuvalent, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s quick ratio has grown at a 44.4% compound annual growth rate (CAGR), from 2.4× to 15.3×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.